198 related articles for article (PubMed ID: 30417946)
1. The translational science of hodgkin lymphoma.
Cirillo M; Reinke S; Klapper W; Borchmann S
Br J Haematol; 2019 Jan; 184(1):30-44. PubMed ID: 30417946
[TBL] [Abstract][Full Text] [Related]
2. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
3. Novel therapy for Hodgkin lymphoma.
Batlevi CL; Younes A
Hematology Am Soc Hematol Educ Program; 2013; 2013():394-9. PubMed ID: 24319210
[TBL] [Abstract][Full Text] [Related]
4. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
5. Current and future immunotherapeutic approaches in Hodgkin lymphoma.
Bröckelmann PJ; Borchmann P; Engert A
Leuk Lymphoma; 2016 Sep; 57(9):2014-24. PubMed ID: 27243940
[TBL] [Abstract][Full Text] [Related]
6. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
7. Lymphomagenesis in Hodgkin lymphoma.
Matsuki E; Younes A
Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
10. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
11. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in the therapy of Hodgkin lymphoma.
Ansell S
Am Soc Clin Oncol Educ Book; 2015; ():e479-82. PubMed ID: 25993212
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
14. Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Diefenbach C; Advani R
Hematol Oncol Clin North Am; 2014 Feb; 28(1):105-22. PubMed ID: 24287071
[TBL] [Abstract][Full Text] [Related]
15. The role of T cells in the microenvironment of Hodgkin lymphoma.
Wein F; Küppers R
J Leukoc Biol; 2016 Jan; 99(1):45-50. PubMed ID: 26320264
[TBL] [Abstract][Full Text] [Related]
16. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
18. [Hodgkin lymphoma].
Nishikori M
Rinsho Ketsueki; 2019; 60(5):447-452. PubMed ID: 31168012
[TBL] [Abstract][Full Text] [Related]
19. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
